Intrahepatic cholangiocarcinoma

This trial tests whether a drug called carfilzomib, given directly to the liver through an implanted pump, is safe for people whose colon, adrenal, or bile duct cancer has spread to the liver and persists after prior pump therapy. Participants receive weekly infusions of the drug…

Researchers are testing whether adding cryoablation, a procedure that freezes tumors, to two drugs can help people with advanced biliary tract cancer that worsened after first-line treatment. The drugs are QL1706, a dual immunotherapy, and lenvatinib, a targeted therapy. The tria…

This trial is testing whether adding a non-invasive ultrasound treatment called histotripsy to the immunotherapy drug durvalumab can strengthen the body's immune response against advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. Histotripsy uses focused sound …

This umbrella trial is testing whether assigning treatment based on a person's tumor genetics can improve outcomes for advanced biliary tract cancers. Participants receive one of several targeted therapies or immunotherapy, depending on their genetic test results. The study aims …

This phase II trial is testing whether a combination of treatments can help people with a type of liver cancer that cannot be removed by surgery. The approach uses local chemotherapy delivered directly to the liver, along with immunotherapy (toripalimab) and a targeted therapy pi…

This phase 2 trial tests VG2025, a modified herpes virus that targets and kills cancer cells while boosting the immune system, in 30 people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer). The virus is injected directly into tumors every four weeks. Ear…

This study tests whether adding the drug Mitazalimab to standard chemotherapy helps people with advanced bile duct cancer live longer. About 160 adults whose cancer has spread or cannot be removed will receive either chemo alone or chemo plus Mitazalimab. Researchers will check s…

This study tests a combination of chemotherapy delivered directly to the liver, an oral targeted drug, and an immunotherapy for people with advanced bile duct cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors. The trial will enroll 30…

This study tests whether a lab test (3D-PTA) that checks which chemotherapy drugs work best on a patient's tumor can improve outcomes after bile duct cancer surgery. About 98 adults with stage II/III bile duct cancer will be randomly assigned to receive either standard capecitabi…

This phase 2 trial tests whether a mix of immunotherapy (iparomlimab and tuvonralimab), chemotherapy (gemcitabine and oxaliplatin), and a targeted drug (lenvatinib) can shrink bile duct and gallbladder cancers enough to be surgically removed. About 29 adults with locally advanced…

This phase 2 trial tests a combination of three drugs—disitamab vedotin, lenvatinib, and a PD-1 inhibitor—for people with HER2-positive advanced biliary tract cancer that cannot be removed by surgery. The study will enroll 65 participants to see how well the treatment shrinks tum…

Researchers want to know whether leftover bile fluid can reveal genetic changes in tumors of people with advanced biliary tract cancer, such as bile duct or gallbladder cancer. Collecting tumor tissue for genetic testing can be difficult or risky in this cancer, so the study coll…

This study tests whether adding a traditional Chinese herbal pill called Yueju to standard cancer therapy can improve quality of life for people with advanced biliary tract cancer. About 210 adults will be randomly assigned to get either the pill or a placebo, without knowing whi…

Researchers at Karolinska University Hospital are following 900 people diagnosed with intrahepatic or perihilar cholangiocarcinoma, two types of bile duct cancer. The study tracks how tumors respond to treatment, how patients feel and function, and changes in biomarkers over time…